196 related articles for article (PubMed ID: 32843506)
1. Neuromuscular Blocking Agents for ARDS: A Systematic Review and Meta-Analysis.
Torbic H; Krishnan S; Harnegie MP; Duggal A
Respir Care; 2021 Jan; 66(1):120-128. PubMed ID: 32843506
[TBL] [Abstract][Full Text] [Related]
2. Early neuromuscular blocking agents for adults with acute respiratory distress syndrome: a systematic review, meta-analysis and meta-regression.
Shao S; Kang H; Tong Z
BMJ Open; 2020 Nov; 10(11):e037737. PubMed ID: 33444180
[TBL] [Abstract][Full Text] [Related]
3. The effect of neuromuscular blocking agents uses in acute respiratory distress syndrome: a systematic review and meta-analysis of randomized controlled trials.
Lyu T; Lee YS; Dhanvijay S; Freebairn R
Minerva Anestesiol; 2021 Mar; 87(3):341-350. PubMed ID: 33300324
[TBL] [Abstract][Full Text] [Related]
4. Validation of neuromuscular blocking agent use in acute respiratory distress syndrome: a meta-analysis of randomized trials.
Chang W; Sun Q; Peng F; Xie J; Qiu H; Yang Y
Crit Care; 2020 Feb; 24(1):54. PubMed ID: 32066488
[TBL] [Abstract][Full Text] [Related]
5. Neuromuscular blockers in the acute respiratory distress syndrome: A meta-analysis.
Hua Y; Ou X; Li Q; Zhu T
PLoS One; 2020; 15(1):e0227664. PubMed ID: 31961896
[TBL] [Abstract][Full Text] [Related]
6. Neuromuscular blocking agents for acute respiratory distress syndrome: an updated meta-analysis of randomized controlled trials.
Zheng Z; Jiang L; Zhang S; Guervilly C; Zhang M; Feng X; Ding J
Respir Res; 2020 Jan; 21(1):23. PubMed ID: 31931794
[TBL] [Abstract][Full Text] [Related]
7. Neuromuscular blocking agents in acute respiratory distress syndrome: updated systematic review and meta-analysis of randomized trials.
Tarazan N; Alshehri M; Sharif S; Al Duhailib Z; Møller MH; Belley-Cote E; Alshahrani M; Centofanti J; McIntyre L; Baw B; Meade M; Alhazzani W;
Intensive Care Med Exp; 2020 Oct; 8(1):61. PubMed ID: 33095344
[TBL] [Abstract][Full Text] [Related]
8. Early short course of neuromuscular blocking agents in patients with COVID-19 ARDS: a propensity score analysis.
Li Bassi G; Gibbons K; Suen JY; Dalton HJ; White N; Corley A; Shrapnel S; Hinton S; Forsyth S; Laffey JG; Fan E; Fanning JP; Panigada M; Bartlett R; Brodie D; Burrell A; Chiumello D; Elhazmi A; Esperatti M; Grasselli G; Hodgson C; Ichiba S; Luna C; Marwali E; Merson L; Murthy S; Nichol A; Ogino M; Pelosi P; Torres A; Ng PY; Fraser JF;
Crit Care; 2022 May; 26(1):141. PubMed ID: 35581612
[TBL] [Abstract][Full Text] [Related]
9. Neuromuscular blocking agents for acute respiratory distress syndrome.
Torbic H; Duggal A
J Crit Care; 2019 Feb; 49():179-184. PubMed ID: 30396789
[TBL] [Abstract][Full Text] [Related]
10. Sedation and neuromuscular blocking agents in acute respiratory distress syndrome.
Bourenne J; Hraiech S; Roch A; Gainnier M; Papazian L; Forel JM
Ann Transl Med; 2017 Jul; 5(14):291. PubMed ID: 28828366
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological agents for adults with acute respiratory distress syndrome.
Lewis SR; Pritchard MW; Thomas CM; Smith AF
Cochrane Database Syst Rev; 2019 Jul; 7(7):CD004477. PubMed ID: 31334568
[TBL] [Abstract][Full Text] [Related]
12. Neuromuscular blocking agents for adult patients with acute respiratory distress syndrome: A meta-analysis of randomized controlled trials.
Tao W; Yang LQ; Gao J; Shao J
J Trauma Acute Care Surg; 2018 Dec; 85(6):1102-1109. PubMed ID: 30462621
[TBL] [Abstract][Full Text] [Related]
13. Best evidence in critical care medicine: The role of neuromuscular blocking drugs in early severe acute respiratory distress syndrome.
Needham CJ; Brindley PG
Can J Anaesth; 2012 Jan; 59(1):105-8. PubMed ID: 22042702
[TBL] [Abstract][Full Text] [Related]
14. Paediatric Acute Respiratory Distress Syndrome Neuromuscular Blockade study (PAN-study): a phase IV randomised controlled trial of early neuromuscular blockade in moderate-to-severe paediatric acute respiratory distress syndrome.
Rudolph MW; Slager S; Burgerhof JGM; van Woensel JBM; Alffenaar JC; Wösten-van Asperen RM; de Hoog M; IJland MM; Kneyber MCJ;
Trials; 2022 Jan; 23(1):96. PubMed ID: 35101098
[TBL] [Abstract][Full Text] [Related]
15. Myorelaxants in ARDS patients.
Hraiech S; Yoshida T; Annane D; Duggal A; Fanelli V; Gacouin A; Heunks L; Jaber S; Sottile PD; Papazian L
Intensive Care Med; 2020 Dec; 46(12):2357-2372. PubMed ID: 33159530
[TBL] [Abstract][Full Text] [Related]
16. Effects of the use of neuromuscular blocking agents on acute respiratory distress syndrome outcomes: A systematic review.
Paramore S
J Am Assoc Nurse Pract; 2018 Jun; 30(6):327-332. PubMed ID: 29878965
[TBL] [Abstract][Full Text] [Related]
17. Early Paralysis for the Management of ARDS.
Grawe ES; Bennett S; Hurford WE
Respir Care; 2016 Jun; 61(6):830-8. PubMed ID: 27094392
[TBL] [Abstract][Full Text] [Related]
18. Neuromuscular blocking agents in acute respiratory distress syndrome: a systematic review and meta-analysis of randomized controlled trials.
Alhazzani W; Alshahrani M; Jaeschke R; Forel JM; Papazian L; Sevransky J; Meade MO
Crit Care; 2013 Mar; 17(2):R43. PubMed ID: 23497608
[TBL] [Abstract][Full Text] [Related]
19. To Block or Not: Updates in Neuromuscular Blockade in Acute Respiratory Distress Syndrome.
Mefford B; Donaldson JC; Bissell BD
Ann Pharmacother; 2020 Sep; 54(9):899-906. PubMed ID: 32111121
[No Abstract] [Full Text] [Related]
20. Paralytics in critical care: not always the bad guy.
Forel JM; Roch A; Papazian L
Curr Opin Crit Care; 2009 Feb; 15(1):59-66. PubMed ID: 19186410
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
